Unfortunately, resistance to ADT eventually emerges, usually manifesting as tumor regrowth associated with an increase in the serum prostate-specific antigen (PSA) levels, and in the case of HRPC, fatal outcomes is usually associated [4,5]. Here, KLK3 is linked to neoplasm.